Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly


Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly




Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

Study Status: Terminated


Condition Intervention Phase
Acromegaly Drug: Octreotide Implant
Drug: Sandostatin LAR Depot
Phase 3

Verified by Endo Pharmaceuticals September, 2013

Sponsored by: Endo Pharmaceuticals
Information provided by: Endo Pharmaceuticals identifier: NCT00765323

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site